IDiyas

For the Inventor, By the Inventor

Beijing, China

Yanping Zhao

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 9.9

ph-index = 2

Forward Citations = 15(Granted Patents)


Company Filing History:

goldMedal16 out of 17 
 
Beijing Tide Pharmaceutical Co., Ltd.
 patents

Years Active: 2019-2025

where 'Filed Patents' based on already Granted Patents

16 patents (USPTO):
1. 12485108 - Method for treating fatty liver disease and/or steatohepatitis (2025-12-02),
2. 12459917 - Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof (2025-11-04),
3. 12410192 - Compound for inhibiting and inducing degradation of EGFR kinase (2025-09-09),
4. 12398118 - Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof (2025-08-26),
5. 12365665 - Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof (2025-07-22),
6. 12180243 - Receptor inhibitor, pharmaceutical composition comprising same, and use thereof (2024-12-31),
7. 11939578 - Double-stranded RNA molecule targeting CKIP-1 and use thereof (2024-03-26),
8. 11938222 - Pregabalin sustained release composition and method for preparing the same (2024-03-26),
9. 11919918 - P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof (2024-03-05),
10. 11905274 - Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof (2024-02-20),
11. 11453690 - Receptor inhibitor, pharmaceutical composition comprising same, and use thereof (2022-09-27),
12. 11414444 - P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof (2022-08-16),
13. 11390609 - Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof (2022-07-19),
14. 11155819 - Double-stranded RNA molecule targeting CKIP-1 and use thereof (2021-10-26),
15. 10329282 - Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof (2019-06-25),

Title: Yanping Zhao: Innovator in Pharmaceutical Development

Introduction

Yanping Zhao is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific kinases involved in various diseases.

Latest Patents

Yanping Zhao holds 14 patents, showcasing his innovative work in the pharmaceutical industry. His latest patents include a compound for inhibiting and inducing degradation of EGFR kinase. This invention provides an EGFR kinase inhibitor according to a general formula and a pharmaceutical composition containing the inhibitor. The invention can be utilized to treat diseases related to EGFR kinase, such as cancer. Another notable patent is for a Rho-associated protein kinase inhibitor, which is represented by a specific formula. This patent also includes a pharmaceutical composition comprising the inhibitor and its use for preventing or treating ROCK-mediated diseases.

Career Highlights

Yanping Zhao is currently associated with Beijing Tide Pharmaceutical Co., Ltd. His work has been instrumental in advancing therapeutic options for patients suffering from various conditions.

Collaborations

Some of his notable coworkers include Hongjun Wang and Liying Zhou, who contribute to the collaborative efforts in their research and development projects.

Conclusion

Yanping Zhao's innovative work in the pharmaceutical sector highlights his commitment to improving healthcare through targeted therapies. His contributions continue to pave the way for advancements in the treatment of serious diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…